Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Immunogenicity and Safety of a New Vaccine Schedule Using the Vaccine Candidate Sm14 Against Schistosomiasis in Adults With a History of S. Mansoni and / or S. Haematobium Infection.

NCT05658614 is registered in ClinicalTrials.gov with Oswaldo Cruz Foundation as lead sponsor.

NCT NCT05658614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Immunogenicity and Safety of a New Vaccine Schedule Using the Vaccine Candidate Sm14 Against Schistosomiasis in Adults With a History of S. Mansoni and / or S. Haematobium Infection.
Lead sponsor
Oswaldo Cruz Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
December 31, 2023
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schistosomiasis haematobium, schistosomiasis mansoni, vaccination; infection